--- title: "Q1 2025 Earnings Forecast for Belite Bio, Inc (NASDAQ:BLTE) Issued By HC Wainwright" description: "Belite Bio, Inc (NASDAQ:BLTE) received Q1 2025 earnings estimates from HC Wainwright, expecting an EPS of {{.Question}}.29, maintaining a 'Buy' rating and a price target of .00. The consensus for curr" type: "news" locale: "en" url: "https://longbridge.com/en/news/211558108.md" published_at: "2024-08-14T11:39:20.000Z" --- # Q1 2025 Earnings Forecast for Belite Bio, Inc (NASDAQ:BLTE) Issued By HC Wainwright > Belite Bio, Inc (NASDAQ:BLTE) received Q1 2025 earnings estimates from HC Wainwright, expecting an EPS of {{.Question}}.29, maintaining a 'Buy' rating and a price target of .00. The consensus for current full-year earnings is (.08) EPS. Other analysts, including Benchmark and Cantor Fitzgerald, reiterated buy and overweight ratings. The stock recently traded at .16, showing a market cap of .49 billion. Armistice Capital recently acquired a new stake in the company, holding 0.53% of shares owned by institutional investors. Belite focuses on developing therapeutics for retinal diseases. Belite Bio, Inc (NASDAQ:BLTE - Free Report) - Research analysts at HC Wainwright issued their Q1 2025 earnings per share (EPS) estimates for shares of Belite Bio in a report issued on Tuesday, August 13th. HC Wainwright analyst Y. Chen expects that the company will post earnings of ($0.29) per share for the quarter. HC Wainwright currently has a "Buy" rating and a $60.00 price target on the stock. The consensus estimate for Belite Bio's current full-year earnings is ($1.08) per share. HC Wainwright also issued estimates for Belite Bio's Q2 2025 earnings at ($0.29) EPS, Q3 2025 earnings at ($0.29) EPS and Q4 2025 earnings at ($0.29) EPS. Several other analysts also recently issued reports on the company. Benchmark reiterated a "buy" rating and set a $57.00 price target on shares of Belite Bio in a research note on Tuesday. Cantor Fitzgerald reiterated an "overweight" rating on shares of Belite Bio in a research note on Thursday, June 20th. **Get Our Latest Research Report on Belite Bio** ## Belite Bio Trading Up 3.3 % BLTE stock opened at $50.16 on Wednesday. The firm has a market cap of $1.49 billion, a PE ratio of -42.51 and a beta of -1.47. Belite Bio has a 1 year low of $20.32 and a 1 year high of $50.66. The company has a fifty day simple moving average of $48.43 and a 200 day simple moving average of $44.90. Belite Bio (NASDAQ:BLTE - Get Free Report) last announced its quarterly earnings results on Monday, May 13th. The company reported ($0.27) EPS for the quarter, topping the consensus estimate of ($0.34) by $0.07. ## Hedge Funds Weigh In On Belite Bio An institutional investor recently bought a new position in Belite Bio stock. Armistice Capital LLC acquired a new stake in Belite Bio, Inc (NASDAQ:BLTE - Free Report) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 36,000 shares of the company's stock, valued at approximately $1,647,000. Armistice Capital LLC owned about 0.13% of Belite Bio as of its most recent filing with the Securities and Exchange Commission (SEC). 0.53% of the stock is currently owned by institutional investors and hedge funds. ## Belite Bio Company Profile (Get Free Report) Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. The company's lead product candidate is LBS-008 (Tinlarebant), an orally administered once-a-day tablet for maintaining the health and integrity of retinal tissues in autosomal recessive Stargardt disease and geographic atrophy patients. ## See Also - Five stocks we like better than Belite Bio - Breakout Stocks: What They Are and How to Identify Them - Is NVIDIA Stock a Buy Ahead of Earnings? - Why Are Stock Sectors Important to Successful Investing? - Instacart Stock Gains Momentum with Profits and AI-Powered Carts - What Does a Stock Split Mean? - Is PROCEPT BioRobotics the Next Big Thing in Surgical Robotics? *This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.* → Secure this "AI Fuel" Stock Before the Billionaires Buy It All (From Behind the Markets) (Ad)## Should you invest $1,000 in Belite Bio right now? Before you consider Belite Bio, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Belite Bio wasn't on the list. While Belite Bio currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys. View The Five Stocks Here ### Related Stocks - [BLTE.US - Belite Bio](https://longbridge.com/en/quote/BLTE.US.md) ## Related News & Research | Title | Description | URL | |-------|-------------|-----| | Belite Bio 完成了針對 Stargardt 病的 DRAGON II 二/三期臨牀試驗的患者入組 | Belite Bio Inc. 已完成針對 tinlarebant 的 2/3 期 DRAGON II 試驗的招募，旨在治療 1 型斯塔加特病 (STGD1)。該試驗包括來自日本、美國和英國的 60 名年齡在 12 到 20 歲之間的青少年 | [Link](https://longbridge.com/en/news/273873856.md) | | 這位 Compass 分析師以看漲的態度開始覆蓋；以下是週一的四大啓動 | 華爾街頂級分析師已對多家公司啓動了覆蓋。羅斯柴爾德公司的哈里·巴特利特將 Chime Financial Inc（納斯達克代碼：CHYM）評級為中性，目標價為 29 美元。高盛的諾亞·波波納克也將 AAR Corp（紐約證券交易所代碼：AI | [Link](https://longbridge.com/en/news/273710688.md) | | Belite Bio, Inc. 贊助的美國存託憑證（納斯達克代碼：BLTE）在 1 月份的空頭頭寸增加了 49.4% | Belite Bio, Inc.（納斯達克代碼：BLTE）在 1 月份的空頭頭寸增加了 49.4%，截至 1 月 30 日，總計為 585,301 股。覆蓋天數比率為 2.8 天，空頭賣出股份佔比為 1.8%。機構投資者活躍，凱通國際資產管 | [Link](https://longbridge.com/en/news/275979339.md) | --- > **Disclaimer**: This article is for reference only and does not constitute any investment advice.